Drugs / Alofanib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04071184 | May 2019 → Oct 2020 | gastric cancer | Russian Pharmaceutical Technologies | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alofanib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04071184 ↗ |
| Action | Inhibit | “Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor.” PMID 36907947 ↗ Mar 2023 |
| Modality | Small molecule | “Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor.” PMID 36907947 ↗ Mar 2023 |
| Route | Intravenous | “Alofanib was administered daily intravenously” PMID 36907947 ↗ Mar 2023 |
| Target | FGFR2 | “Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor.” PMID 36907947 ↗ Mar 2023 |